Inhibition of Superoxide Generation and Associated Nitrosative Damage Is Involved in Metallothionein Prevention of Diabetic Cardiomyopathy

TABLE 2

Blood pressure and cardiac function in the mice 2 weeks after STZ treatment

Cardiac function parameters Wild type
MT-TG
Control Diabetes Diabetes/insulin Control Diabetes
n 11 9 3 10 10
Blood pressure (mmHg)
    Systolic pressure 94.5 ± 5.6 102.4 ± 6.7 97.5 ± 5.6 94.1 ± 4.7 95.6 ± 1.0
    Diastolic pressure 70.7 ± 8.1 76.1 ± 5.5 72.4 ± 6.1 73.7 ± 3.1 70.0 ± 8.4
Cardiac function
    Heart rate (bpm) 402.3 ± 10.0 451.2 ± 18.7* 406.0 ± 3.6 421.8 ± 7.8 434.4 ± 13.1
    LVEDP (mmHg) 5.8 ± 1.0 17.1 ± 3.0* 5.7 ± 0.5 7.7 ± 2.2 7.8 ± 1.2
    LVMDP (mmHg) −0.6 ± 1.2 1.5 ± 1.4 −0.9 ± 1.0 −0.6 ± 2.2 −0.7 ± 1.8
    LVPSP (mmHg) 103.9 ± 1.9 98.9 ± 1.6 107.6 ± 4.1 103.4 ± 4.9 103.1 ± 5.6
    Maximum dP/dt (mmHg/s) 7,155.7 ± 318.8 5,054.9 ± 532.8* 7,487.1 ± 273.5 7,311.2 ± 503.8 7,380.7 ± 702.0
    Maximum dP/dt DCON (ms) 37.6 ± 3.4 33.3 ± 4.9 40.4 ± 0.6 36.1 ± 3.8 37.5 ± 4.1
    τ (ms) 20.4 ± 1.8 29.1 ± 3.9* 22.2 ± 0.7 20.1 ± 1.9 21.4 ± 3.1
    Formula R (ms) 44.3 ± 2.6 43.0 ± 3.6 44.8 ± 2.8 40.9 ± 2.8 40.3 ± 3.0
  • Data are means ± SE. LVPSP, left ventricular peak systolic pressure; DCON, duration of contraction; τ, time constant of relaxation; Formula R, time constant duration of half-relaxation.

  • *

    * P < 0.05 vs. wild-type control.

This Article

  1. Diabetes vol. 54 no. 6 1829-1837